The Wolverine Stack: BPC-157 and TB-500 Together — Rationale, Evidence, and 2026 Status

The "wolverine stack" is the informal name for combining BPC-157 and TB-500 in a single tissue-repair protocol. The nickname — borrowed from the fast-healing comic-book character — captures the appeal: two peptides, each studied for a different part of the healing process, used together in the hope of faster recovery from tendon, ligament, muscle, and soft-tissue injury. The combination is one of the most searched peptide stacks. It is also one where the gap between popularity and evidence is widest, and where the regulatory picture changed materially in July 2026.

This guide covers what each component is thought to contribute, what evidence exists for BPC-157 and TB-500 together, how the stack is typically structured, and where it stands with the FDA.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

What Is the Wolverine Stack?

The wolverine stack is not a defined product or a standardized formulation. It is a pairing: BPC-157, a 15-amino-acid peptide derived from a protective protein in gastric juice, used alongside TB-500, a synthetic fragment of the protein thymosin beta-4. Where it has been used, the two have typically been administered as separate preparations. The term is also used loosely for larger "stacks" that add other peptides — which is one reason it is worth asking exactly what a given preparation contains.

In clinical shorthand the same pairing is often called "BPC + TB." Our existing TB-500 dosing reference describes it as "a frequent clinical pattern for tissue repair protocols."

Why BPC-157 and TB-500 Are Combined

The rationale is complementary mechanisms. Each peptide is studied for a different layer of tissue repair biology, so the argument runs that together they cover more of the process than either alone.

What BPC-157 Is Thought to Add

BPC-157's preclinical literature is one of the largest of any short-chain peptide, and it points consistently toward protection and repair: accelerated tendon healing in surgical transection models, ligament and muscle injury recovery, and protective effects in gastrointestinal injury. Proposed mechanisms include formation of new blood vessels, nitric-oxide synthesis, up-regulation of growth factors, and suppression of inflammatory signals. See BPC-157 mechanism of action for detail.

What TB-500 Is Thought to Add

TB-500 derives from the actin-binding region of thymosin beta-4. Actin is the structural filament cells rebuild when they change shape and move, so regulating it is central to getting repair cells to the site of an injury. See TB-500 and actin-driven cell migration.

The stack's premise, then, is BPC-157 supporting blood supply and inflammatory control while TB-500 supports the migration of repair cells. For a direct comparison of the two — which tissues each has been studied in and how they differ — see thymosin beta-4 vs BPC-157.

What the Evidence Shows for the Combination

This is the most important section, and the answer is short: there are no published human trials of BPC-157 and TB-500 used together. The case for the wolverine stack is built by adding up the evidence for each component and the mechanistic logic of combining them — not from studies of the combination itself.

The component evidence is itself limited in humans:

• BPC-157. Substantial and consistent preclinical data, small clinical reports, and pilot studies. FDA's July 2026 briefing found a lack of effectiveness evidence for the nominated uses (including tendonitis), dose-response relationships not established, and insufficient clinical safety information to characterize its human safety profile. Our BPC-157 clinical research review lays out the data by category.
• TB-500. FDA's briefing found no medical literature in which TB-500 was administered to patients for any condition, and cited an in-vitro study in which it did not induce wound healing in fibroblast cultures.

Combining two compounds also combines their uncertainties. Interactions, additive effects on angiogenesis, and immunogenicity risk from two injected peptides have not been studied together.

How the Stack Is Typically Structured

Because neither peptide is FDA-approved, there is no labeled dose for either component and none for the combination. What existing clinical-practice references describe is a structure rather than numbers. Our TB-500 reference describes frameworks that commonly include:

• A loading phase with more frequent dosing for the first several weeks
• A maintenance phase at reduced frequency afterwards
• Cycling in defined treatment blocks with rest periods between

Subcutaneous injection is the most common route. If lawful access is confirmed, dose magnitudes for each component would be prescriber-determined — see BPC-157 dosage for how that decision is framed, and our peptide calculator for reconstitution arithmetic.

Both peptides are in Category 2 and the subject of FDA's July 2026 proposal not to list them, so compounded access to either — alone or combined — is in serious doubt. Check the tracker before planning anything.

Safety Considerations

The combined safety picture is the sum of two incompletely characterized profiles:

• Injection-site reactions are the most commonly described issue in clinical experience with either peptide.
• Angiogenesis and malignancy. Both peptides are studied for promoting new blood vessel growth. That is a theoretical concern in patients with active or recent cancer, and it is additive when the two are combined.
• Immunogenicity. FDA flagged unassessed immunogenicity risk for both as injectable peptides.
• Product identity. FDA described both as not well-characterized. TB-500 in particular is described differently across sources — FDA's briefing describes a seven-amino-acid acetylated fragment, while other references describe a longer fragment — so confirming exactly what a preparation contains matters.

See BPC-157 side effects for detail.

Regulatory Status in 2026

FDA's briefing documents for the July 23, 2026 Pharmacy Compounding Advisory Committee meeting proposed not adding BPC-157 or TB-500 to the 503A Bulks List — see BPC-157 and the FDA 503A decision and TB-500 and the FDA 503A decision. A proposal is not a final rule, but it means lawful 503A compounding access to either component is in serious doubt. Check our FDA peptide status tracker for current status and confirm availability with the compounding partner before any protocol is planned.

Both peptides are prohibited at all times under WADA's anti-doping rules, which matters for competitive athletes considering the stack for injury recovery.

Where the Wolverine Stack Fits

For a practice, the wolverine stack is best treated as what it is: a mechanistically reasoned combination with no direct human trial data, built on two components whose compounding status is under active FDA challenge. Our peptides for healing hub places it among the other repair peptides, including options with a clearer regulatory position. For surgical contexts specifically, see BPC-157 for post-surgical recovery.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers.

Frequently Asked Questions

What is the wolverine stack?

The wolverine stack is an informal name for combining BPC-157 and TB-500 in one tissue-repair protocol. It is not a standardized formulation; the components may be given separately or combined in one compounded vial.

Does the wolverine stack work?

There are no published human trials of BPC-157 and TB-500 used together. The rationale comes from each peptide's preclinical research and their complementary proposed mechanisms. Human evidence for each component alone is limited.

Can you take BPC-157 and TB-500 together?

They are commonly combined in clinical practice, but the combination has not been studied for safety or effectiveness as a pair. Any use is a prescriber decision, and FDA's July 2026 proposal not to add either peptide to the 503A Bulks List affects whether they can be lawfully compounded.

What is the wolverine stack dosage?

There is no established dose for either component or for the combination. Existing clinical references describe loading, maintenance, and cycling frameworks; dose amounts are prescriber-determined for the specific preparation.

Is the wolverine stack legal?

Neither BPC-157 nor TB-500 is FDA-approved. In July 2026 FDA proposed not adding either to the 503A Bulks List, which places compounded access in doubt. Both are prohibited under WADA rules. Check the FDA tracker for current status.

What are the risks of combining BPC-157 and TB-500?

Injection-site reactions are the most commonly described issue. Theoretical concerns include additive effects on blood-vessel growth in patients with a cancer history, immunogenicity from injected peptides, and uncertainty about what a given product actually contains.